Its enhanced efficacy and safety profile, characterized by its ability to cross the blood-brain barrier and limited activity against wild-type EGFR, make it a valuable treatment option for EGFR-mutated NSCLC [10, 11]. Here, EGFR is linked to non-small cell lung carcinoma.